Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $37

Benzinga · 2d ago
Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $32 to $37.